Skip to main content

Rotavirus Vaccine — AVANT Immunotherapeutics/GlaxoSmithKline

89–12, RIX4414

    Drugs in R & D volume 5, pages 113–115 (2004)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    49,54 €

    Price includes VAT (Finland)
    Tax calculation will be finalised during checkout.

    Table I
    Table II

    References

    1. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial. Lancet 354: 287–290, 24 Jul 1999

      PubMed  Article  CAS  Google Scholar 

    2. Vesikari T, Karvonen A, Espo M, et al. Efficacy evaluation on an oral human rotavirus vaccine on previously uninfected Finnish infants. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 249 (plus oral presentation), 27 Sep 2002

      Google Scholar 

    3. AVANT Immunotherapeutics Inc. AVANT announces results from 2nd year surveillance extension of the phase II rotavirus vaccine study. Media Release [3 pages], 4 May 2000. Available from URL: http://www.avantimmune.com

      Google Scholar 

    4. Bernstein DI, Sack DA, Reisinger K, et al. Second year evaluation of live attenuated oral rotavirus vaccine, 89–12, in healthy infants. Clinical Infectious Diseases 31: 222, Jul 2000

      Google Scholar 

    5. Pérez-Schael I, Linhares AC, Guerrero ML, et al. Protective efficacy of an oral human rotavirus vaccine in Latin American infants. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy: Late Breaker Abstracts: 18, 27 Sep 2002

      Google Scholar 

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Rotavirus Vaccine — AVANT Immunotherapeutics/GlaxoSmithKline. Drugs R D 5, 113–115 (2004). https://doi.org/10.2165/00126839-200405020-00010

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.2165/00126839-200405020-00010

    Keywords

    • Placebo Recipient
    • Vaccine Group
    • Vaccine Recipient
    • Oral Polio Vaccine
    • Unvaccinated Infant